Welcome to our dedicated page for EvokAI Creative news (Ticker: OKAIF), a resource for investors and traders seeking the latest updates and insights on EvokAI Creative stock.
EvokAI Creative Labs Inc. (OTCQB: OKAIF) generates news that centers on MedTech innovation, regulatory milestones, and capital markets developments. The company describes itself as an AI-powered medical technology business focused on transformational tools for the healthcare sector, particularly in the monitoring and management of movement disorders such as Parkinson’s disease.
News coverage for EvokAI often highlights progress with its MDM Flex Sensor and the EvokAI Movement Disorder Monitor (MDM). Key updates include the initiation and completion of the CE Mark process for the MDM Flex Sensor, which the company presents as a major step toward broader deployment of its technology in Europe. These articles detail how the sensor is designed to provide precise, continuous assessment of movement disorders and to support personalized treatment decisions through AI-based analysis.
Investors and healthcare observers will also find news related to EvokAI’s research collaborations and validation efforts. The company has reported working with VTT Technical Research Centre of Finland on its Parkinson’s disease technology and has referenced clinical trials and studies to support safety and efficacy claims. Such announcements provide context on the scientific and clinical foundations of its products.
From a market perspective, EvokAI’s news flow includes trading and listing updates, such as the commencement of trading on the OTCQB Venture Market under the symbol OKAIF and the company’s continued listing on the TSX Venture Exchange under OKAI. Corporate actions, including the announced 10:1 share consolidation and related changes to share structure, are also covered. Readers who follow OKAIF news can track how regulatory approvals, research progress, and capital markets decisions intersect in the company’s development.
EvokAI Creative Labs has announced the completion of its previously disclosed 10:1 share consolidation, effective February 05, 2025. Following the consolidation, the company will have approximately 7,605,493 common shares outstanding.
The consolidation will be implemented under new CUSIP (30053J200) and ISIN (CA30053J2002) numbers. Shareholders holding uncertificated shares will have their accounts automatically adjusted by Endeavor Trust or their respective brokers. Registered shareholders with physical certificates will receive instructions for surrendering their current certificates for post-consolidation replacements.
The company expects this consolidation to potentially increase financial community interest, broaden its investor base, improve trading liquidity, and reduce shareholder transaction costs.
Summary not available.
Summary not available.
Summary not available.